- Home
- FHTX vs MUX Comparison
FHTX vs MUX Comparison
Compare FHTX & MUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- MUX
- Stock Information
- Founded
- FHTX 2015
- MUX 1979
- Country
- FHTX United States
- MUX Canada
- Employees
- FHTX N/A
- MUX N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- MUX Precious Metals
- Sector
- FHTX Health Care
- MUX Basic Materials
- Exchange
- FHTX Nasdaq
- MUX Nasdaq
- Market Cap
- FHTX 513.7M
- MUX 443.5M
- IPO Year
- FHTX 2020
- MUX N/A
- Fundamental
- Price
- FHTX $5.14
- MUX $7.98
- Analyst Decision
- FHTX Strong Buy
- MUX Strong Buy
- Analyst Count
- FHTX 5
- MUX 2
- Target Price
- FHTX $13.80
- MUX $15.63
- AVG Volume (30 Days)
- FHTX 197.3K
- MUX 524.3K
- Earning Date
- FHTX 11-04-2024
- MUX 11-05-2024
- Dividend Yield
- FHTX N/A
- MUX N/A
- EPS Growth
- FHTX N/A
- MUX N/A
- EPS
- FHTX N/A
- MUX 2.07
- Revenue
- FHTX $25,515,000.00
- MUX $199,634,000.00
- Revenue This Year
- FHTX N/A
- MUX $22.76
- Revenue Next Year
- FHTX $11.54
- MUX $18.67
- P/E Ratio
- FHTX N/A
- MUX $3.86
- Revenue Growth
- FHTX N/A
- MUX 47.02
- 52 Week Low
- FHTX $2.70
- MUX $5.92
- 52 Week High
- FHTX $10.25
- MUX $12.50
- Technical
- Relative Strength Index (RSI)
- FHTX 27.35
- MUX 40.50
- Support Level
- FHTX $4.69
- MUX $7.78
- Resistance Level
- FHTX $5.70
- MUX $8.45
- Average True Range (ATR)
- FHTX 0.61
- MUX 0.40
- MACD
- FHTX -0.14
- MUX -0.05
- Stochastic Oscillator
- FHTX 16.24
- MUX 13.33
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About MUX McEwen Mining Inc.
McEwen Mining Inc is a mining and minerals production and exploration company focused on precious and base minerals in Argentina, Mexico, and the United States. The company's overall revenue is principally derived from the production of gold and silver. The company owns and operates the wholly-owned El Gallo 1 mine in Mexico, and has a minority shareholding in the company that operates the San Jose mine in Argentina. More than half the company's gold output is produced by the El Gallo 1 mine. The remaining gold production, and the majority of silver production, is produced by the San Jose mine. Geographically, the majority is from Canada.